Editorial Commentary
Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management
AME Clinical Trials Review
2025;
3:
36
.
(25 August 2025)
Editorial Commentary
Advancing HER2-positive breast cancer treatment: the promise and challenges of trastuzumab deruxtecan over trastuzumab emtansine—DESTINY-Breast03 trial
AME Clinical Trials Review
2025;
3:
35
.
(25 August 2025)
Editorial Commentary
Balancing treatment efficacy and complications in early-onset locally advanced rectal cancer
AME Clinical Trials Review
2025;
3:
34
.
(25 August 2025)
Editorial Commentary
Transforming post-surgical lung cancer recovery: app-based approach to telerehabilitation
AME Clinical Trials Review
2025;
3:
33
.
(25 August 2025)
Editorial Commentary
Exploring the role of triplet therapy in relapsed chronic lymphocytic leukemia (CLL) and an emerging role for ctDNA in CLL: key takeaways from the CLL2-BAAG trial
AME Clinical Trials Review
2025;
3:
32
.
(25 August 2025)
Editorial Commentary
Treatment of newly diagnosed transplant ineligible multiple myeloma: is there a BENEFIT to adding bortezomib to the standard backbone?
AME Clinical Trials Review
2025;
3:
31
.
(25 June 2025)
Editorial Commentary
COSMIC-312: lessons learned from another combination immune checkpoint and multi-kinase inhibitor trial
AME Clinical Trials Review
2025;
3:
30
.
(25 June 2025)
Editorial Commentary
Nutrition following esophagectomy, what’s best?
AME Clinical Trials Review
2025;
3:
29
.
(25 June 2025)
Editorial Commentary
The new kid on the block: will asciminib change frontline therapy of chronic myeloid leukemia patients?
AME Clinical Trials Review
2025;
3:
28
.
(25 June 2025)
Editorial Commentary
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer
AME Clinical Trials Review
2025;
3:
27
.
(25 June 2025)
Editorial Commentary
Lung cancer detection by electronic nose: ready for prime time?
AME Clinical Trials Review
2025;
3:
26
.
(25 June 2025)
Editorial Commentary
Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients
AME Clinical Trials Review
2025;
3:
25
.
(25 June 2025)
Editorial Commentary
Immunotherapy as the new standard of care for advanced endometrial cancer
AME Clinical Trials Review
2025;
3:
24
.
(25 June 2025)
Editorial Commentary
Should routine dual antiplatelet therapy be recommended after elective coronary artery bypass surgery: insights from the DACAB-FE trial
AME Clinical Trials Review
2025;
3:
23
.
(25 June 2025)
Editorial Commentary
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial: the additive value of radiation therapy in the management of patients with lymphoma
AME Clinical Trials Review
2025;
3:
22
.
(25 June 2025)
Review Article
Is it time to recommend dual antiplatelet therapy for all following coronary artery bypass graft surgery?—an updated review of clinical trials
AME Clinical Trials Review
2025;
3:
21
.
(25 June 2025)
Editorial Commentary
Lessons from FOWARC: moving towards the more precise use of radiation therapy in the era of total neoadjuvant therapy
AME Clinical Trials Review
2025;
3:
20
.
(25 April 2025)
Editorial Commentary
Stereotactic ablative radiotherapy as a novel strategy in patients with oligometastatic hepatocellular carcinoma
AME Clinical Trials Review
2025;
3:
19
.
(25 April 2025)
Editorial Commentary
Finding the RIGHT Choice in patients with clinically aggressive ER-positive HER2-negative metastatic breast cancer
AME Clinical Trials Review
2025;
3:
18
.
(25 April 2025)
Editorial Commentary
Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression
AME Clinical Trials Review
2025;
3:
17
.
(25 April 2025)
Editorial Commentary
Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer
AME Clinical Trials Review
2025;
3:
16
.
(25 April 2025)
Editorial Commentary
Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC
AME Clinical Trials Review
2025;
3:
15
.
(25 April 2025)
Editorial Commentary
Revumenib: a new potential targeted therapy for KMT2A-rearranged acute leukemia
AME Clinical Trials Review
2025;
3:
14
.
(25 April 2025)
Editorial Commentary
Intravascular imaging guided optimization in complex percutaneous coronary intervention (PCI)—does clinical presentation matter?
AME Clinical Trials Review
2025;
3:
13
.
(25 April 2025)
Editorial Commentary
Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?
AME Clinical Trials Review
2025;
3:
12
.
(25 April 2025)
Editorial Commentary
A SMART-er approach to upfront unresectable pancreatic adenocarcinoma
AME Clinical Trials Review
2025;
3:
11
.
(25 April 2025)
Editorial Commentary
Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial
AME Clinical Trials Review
2025;
3:
10
.
(25 February 2025)
Editorial Commentary
How do we improve chemoimmunotherapy in gastroesophageal adenocarcinoma?
AME Clinical Trials Review
2025;
3:
9
.
(25 February 2025)
Editorial Commentary
Final survival analysis from the LACC trial defines the current standard of care in surgical treatment of cervical cancer, however does not mark the final say
AME Clinical Trials Review
2025;
3:
8
.
(25 February 2025)
Editorial Commentary
Targeting menin in relapsed or refractory acute myeloid leukaemia—where the rubber hits the road
AME Clinical Trials Review
2025;
3:
7
.
(25 February 2025)